following a full submission:
standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae (Acarizax®) is accepted for restricted use within NHSScotland.
Indication under review: in adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific immunoglobulin E (IgE) with at least one of the following conditions:
- persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication
- house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.
SMC restriction: persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.
In three double-blind phase III studies, one year’s treatment with Acarizax®, in combination with standard care, significantly improved a combined measure of rhinitis symptom severity and medication use (total combined rhinitis score) compared with placebo.
Medicine details
- Medicine name:
- D. pteronyssinus & D. farinae allergen extracts (Acarizax)
- SMC ID:
- SMC2885
- Indication:
Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:
- persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication
- house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment
- Pharmaceutical company
- ALK-Abello Ltd
- BNF chapter
- Immunological products and vaccines
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 August 2026